Abstract:AIM: To evaluate the efficacy of long-term, low- dose intra-muscular hepatitis B immunoglobulin (HBIg) combined with lamivudine (LAM) in patients who received orthotopic liver transpl- ants (OLT) and have been followed up for acute or chronic HBV-related end-stage liver disease. METHODS: The liver transplantation recipi- ents (n = 173) who have been followed up and received antiviral prophylaxis post-OLT were divided into 3 sub-groups according to their post-OLT antiviral therapy, which were group A (LAM monotherapy, n = 2), group B (HBIg and LAM therapy, n = 168) and group C (HBIg andADF therapy n = 3). All the patients received LAM treatment for 1 or 2 wk ahead of OLT. Ei- ther LAM (100 mg) or ADF (adefovir dipivoxil, 10 mg) was administered orally every day. HBIg were administered intravenously during the first post-operative week (total 5000 or 10 000 U according to HBV copies/L pre-operative) and intramuscularly thereafter (400 U per time, the interval can be adjusted according to HBsAb titer in the blood) to maintain an HBsAb titer > 300 U/L within 1 mo, > 200 U/L between 2-3 mo and > 100 U/L beyond 3 mo after operation. Mean follow-up period was 20.8 ± 14 mo. The periodical investigation for the liver function, the serological HBV and the analyses of liver tis- sues by immunohistochemistry were performed. The recurrent HB and the death suffered from it were recorded and analyzed in this research. The recurrence rates of HBV infection between UCLA and our institute were statistically ana- lyzed. RESULTS: Four patients experienced HBV recurrence overall. One patient in group A ex- perienced HBV recurrence (1 week after OLT) and positive HBV DNA (2 months after OLT) associated with an increase in serum alanine aminotransferase. The treatment resistance of LAM was defined and the recipient died of the multiple organ failure 8 months after OLT. Re- current HBV appeared in 3 patients, whose HBV DNA levels in the pre-OLT blood were more than 108 copies/L, in group B (12 d, 12 mo and 1.5 mo after OLT respectively). The pre- and post- operative HBeAg and HBV DNA were always positive in the first case whose blood HBsAb titer was far lower than programming effective one. The treatment resistance of HBIg was de- fined and the patient died of fulminant hepatitis 11 mo after OLT. The second case became an HBsAg carrier after HBV recurrence and was dead due to tumor recurrence 15 mo after OLT. The third case was fine with the treatment of HBIg combined with ADF and was negative for HBsAg after 5.5 mo. The HBV mutation might exist in both of the second and third case. Noneof group C had HBV recurrence. The HBV recur- rence rate under the prophylaxis of HBIg com- bined with LAM was 1.8% (3/168). Intra-muscu- lar HBIg was tolerated well in all the cases. The study showed no difference between UCLA and our institute (χ2 = 0.280 37), and the expenditure was 3000-4000 US dollars per year. CONCLUSION: The low-dose intra-muscular HBIg combined with LAM is efficacious in the long-term prophylaxis of hepatitis B recurrence after OLT. The total expenditure of prophylaxis is lower. ADF shows efficacy against the HBV- YMDD lamivudine-resistant mutation and may be a more efficacious agent for the prophylaxis of HBV recurrence after OLT.

Section 14. Combination of Entecavir Plus Low-Dose On-Demand Hepatitis B Immunoglobulin is Effective With Very Low Hepatitis B Recurrence After Liver Transplantation

Entecavir Combined with Short-term Hepatitis B Immunoglobulin in Preventing Hepatitis B Virus Recurrence in Liver Transplant Recipients

The role of entecavir in preventing hepatitis B recurrence after liver transplantation

Prevention and risk factors of hepatitis B recurrence after living donor liver transplantation

Impact of Human Leukocyte Antigen Matching on Hepatitis B Virus Recurrence after Liver Transplantation.

HBV Recurrence Lowered by Lamivudine/hbig Combination Therapy in Liver Transplant Patients: Ten-Year Experience

Efficacy and Safety of 12 Weeks-Entecavir Treatment in HBeAg-negative Chronic Hepatitis B Patients with Acute-on-chronic Liver Failure in Comparison to Lamivudine

Hepatitis B immunoglobulins and/or lamivudine for preventing hepatitis B recurrence after liver transplantation: A systematic review

Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis

Low-dose intra-muscular hepatitis B immunoglobulin combined with lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation

Low‐dose anti‐hepatitis B immunoglobulin regimen as prophylaxis for hepatitis B recurrence after liver transplantation

Effect of Lamivudine and Hepatitis B Immunoglobulin for Prevention of Recurrent Hepatitis B after Liver Transplantation

[17-year study on the curative effect of treatment to prevent the recurrence of hepatitis B in different risk groups after liver transplantation]

Antiviral prophylaxis against hepatitis B recurrence after liver transplantation: Current concepts

INTRAMUSCLAR LOW-DOSE HEPATITIS B IMMUNE GLOBULIN COMBINED WITH LAMIVUDINE FOR PROPHYLAXIS AGAINST HEPATITIS B RECURRENCE AFTER LIVERTRANSPLANTATION

Reevaluation of the Effect of Lamivudine Therapy Preoperative to Prevent Hbv Recurrence after Liver Transplantation

Prevention and Treatment of Hepatitis B Recurrence after Liver Transplantation.

HBIG Remains Significant in the Era of New Potent Nucleoside Analogues for Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation

Efficacy of Newer Nucleos(t)ide Analogs After Hepatitis B Immunoglobulin Discontinuation Against Hepatitis B and D Recurrence in Liver Transplant Recipients

Strategy of long-term anti-HBV treatment after liver transplantation for patients with HBV related liver disease

Clearance of HBsAg in patients with chronic hepatitis B treated by entecavir plus Peg IFNα-2b following initial entecavir monotherapy